Verrica Pharmaceuticals Inc. (NASDAQ:VRCA – Get Free Report) was the target of a significant drop in short interest during the month of May. As of May 31st, there was short interest totalling 2,270,000 shares, a drop of 27.9% from the May 15th total of 3,150,000 shares. Currently, 8.7% of the company’s shares are sold short. Based on an average trading volume of 381,600 shares, the short-interest ratio is presently 5.9 days.
Analyst Upgrades and Downgrades
Several brokerages have recently commented on VRCA. HC Wainwright reiterated a “neutral” rating on shares of Verrica Pharmaceuticals in a research report on Tuesday, April 8th. Wall Street Zen raised shares of Verrica Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, May 22nd. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Verrica Pharmaceuticals in a research report on Wednesday, May 14th. Five investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $8.00.
Read Our Latest Report on VRCA
Hedge Funds Weigh In On Verrica Pharmaceuticals
Verrica Pharmaceuticals Price Performance
Shares of VRCA stock opened at $0.58 on Thursday. The stock has a market cap of $53.53 million, a PE ratio of -0.48 and a beta of 1.75. The stock has a 50-day moving average of $0.54 and a 200-day moving average of $0.63. Verrica Pharmaceuticals has a one year low of $0.38 and a one year high of $8.98.
Verrica Pharmaceuticals (NASDAQ:VRCA – Get Free Report) last issued its earnings results on Tuesday, May 13th. The company reported ($0.10) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.04. The firm had revenue of $3.44 million during the quarter, compared to the consensus estimate of $2.53 million. As a group, research analysts anticipate that Verrica Pharmaceuticals will post -1.46 earnings per share for the current year.
Verrica Pharmaceuticals Company Profile
Verrica Pharmaceuticals Inc, a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts.
Featured Stories
- Five stocks we like better than Verrica Pharmaceuticals
- How to Calculate Return on Investment (ROI)
- Chime’s Smart IPO: Half the Valuation, Double the Strength
- 3 Defense Stocks Set to Benefit From Increased Military Spending
- Why Quantum Computing Inc. Is the Quiet Winner in Quantum Stocks
- What is Put Option Volume?
- 3 Catalysts in 7 Days: Archer’s Growth Story Just Accelerated
Receive News & Ratings for Verrica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verrica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.